Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL564157 | 0.88 | — | — | |
| Cysteamine SCHEMBL27629958 | 0.82 | RNPEP (0.48) | CYP3A4TSHRALDH1A1LMNAMAPT | |
| Urea SCHEMBL28501633 | 0.71 | — | — | |
| SCHEMBL19042804 | 0.69 | — | — | |
| SCHEMBL5971223 | 0.69 | — | — | |
| Urea SCHEMBL28460805 | 0.68 | — | — | |
| Carbamic Acid SCHEMBL27915357 | 0.68 | — | — | |
| Acetic Acid SCHEMBL4032886 | 0.66 | — | — | |
| SCHEMBL5469952 | 0.66 | RNPEP (0.39) | CYP3A4ALDH1A1LMNAMAPTBLM | |
| SCHEMBL5470071 | 0.66 | RNPEP (0.38) | CYP3A4ALDH1A1LMNAMAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189567-A1 | Compound having affinity with calcified tissue | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1609797-A1 | COMPOUND HAVING AFFINITY WITH CALCIFIED TISSUE | Nihon Medi-Physics Co., Ltd. (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-6660863-B2 | Reacting an cycloheptatriene nitrile compound with nortropane compound | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2003-12-09 | — | — | US | disclosed |
| US-20030186845-A1 | Compositions for preventing urinary calculus | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2003-10-02 | — | — | US | disclosed |
| US-6596868-B2 | Reacting a cycloheptatriene derivative with a primary amine or ammonia in the presence of a base | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| EP-1323433-A1 | COMPOSITIONS FOR PREVENTING URINARY CALCULUS | Nihon Medi-Physics Co., Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-20030109708-A1 | Process for synthesizing anhydroecgonine derivative | NIHON MEDI-PHYSICS CO., LTD. | 2003-06-12 | — | — | US | disclosed |
| US-20010020096-A1 | Process for synthesizing anhydroecgonine derivative | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2001-09-06 | — | — | US | disclosed |
| EP-1127887-A1 | Process for synthesizing anhydroecgonine derivative | NIHON MEDI-PHYSICS Co., Ltd. (JP) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189567-A1 | Compound having affinity with calcified tissue | SLC7A1, MBNL1, SHBG | CYP3A4 3511/4885TSHR 879/4885ALDH1A1 959/4885 |
| US-20030109708-A1 | Process for synthesizing anhydroecgonine derivative | CES2, NPR1, OPRL1 | CYP3A4 549/4885TSHR 3513/4885ALDH1A1 739/4885 |
| US-20010020096-A1 | Process for synthesizing anhydroecgonine derivative | CES2, NPR1, OPRL1 | CYP3A4 549/4885TSHR 3513/4885ALDH1A1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.